JP Morgan Chase
TVTX icon

JP Morgan Chase’s Travere Therapeutics TVTX Stock Holding History

JP Morgan Chase’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,600
Closed -$1.09M – 7907
2025
Q4 		$1.09M Buy
+28,600
New +$930K ﹤0.01% 4544
2025
Q3 		– Sell
-1,500
Closed -$22.2K – 7733
2025
Q2 		$22.2K Buy
+1,500
New +$24.9K ﹤0.01% 6146
2025
Q1 		– Sell
-5,900
Closed -$103K – 7739
2024
Q4 		$103K Buy
+5,900
New +$104K ﹤0.01% 5750
2024
Q2 		– Sell
-70,000
Closed -$540K – 7752
2024
Q1 		$540K Hold
70,000
– – ﹤0.01% 4741
2023
Q4 		$629K Buy
+70,000
New +$510K ﹤0.01% 4647

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase's TVTX Position: Q1 2026 in Review

JP Morgan Chase reduced its Travere Therapeutics (TVTX) stake by 10% in Q1 2026, selling an estimated $988K and leaving 288,551 shares worth $7.98M. The position accounts for ﹤0.01% of the portfolio, ranked #2885.

JP Morgan Chase first reported a position in TVTX in Q4 2015 and has held it in 41 quarters since. The position peaked at $35.2M in Q4 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • JP Morgan Chase held 288,551 shares of Travere Therapeutics worth $7.98M as of Q1 2026.
  • JP Morgan Chase sold 33,064 Travere Therapeutics shares in Q1 2026, an estimated $988K.
  • Travere Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2885 holding.
  • JP Morgan Chase first reported a position in Travere Therapeutics in Q4 2015 and has held it in 41 quarters since.
  • JP Morgan Chase's Travere Therapeutics position peaked at $35.2M in Q4 2021.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.